Apple Inc. (AAPL), Sigma-Aldrich Corporation (SIAL) and Novo Nordisk A/S (ADR) (NVO): Carderock Capital Management Inc’s Top 3 Equity Picks

Carderock Capital Management Inc reported that the value of its equity portfolio depreciated to $199.2 million at the end of 2Q2015. The fund’s equity portfolio was valued at $206.5 million at the end of the previous quarter.

The movement in equity portfolio value came on the back of a number of changes to the portfolio mix. Carderock Capital Management Inc initiated fresh positions in five stocks during 2Q, with the largest new buys being Snap-on Incorporated (NYSE:SNA) and WPP PLC (NASDAQ:WPPGY).

In other measures, the fund sold out of six stocks during the latest quarter, with BCE Inc. (USA) (NYSE:BCE) bearing the brunt.

Carderock Capital Management Inc also took the opportunity in 2Q to increase exposure to some 38 stocks, among them Mastercard Inc (NYSE:MA) and Nike Inc (NYSE:NKE).

The fund also reduced holdings in another 33 stocks, among them Chevron Corporation (NYSE:CVX), Canadian National Railway (USA) (NYSE:CNI) and Toronto-Dominion Bank (NYSE:TD).

In terms of sectors, Carderock Capital Management Inc has its best bet in Technology industry, which accounts for 24% of its equity portfolio. The fund is also active in Healthcare sector, making up 23% of its portfolio.

Here is a brief look at Carderock Capital Management Inc’s top 3 equity picks overall in terms of dollar value and how it played them in 2Q.

Stake in Apple (AAPL) up slightly

Carderock Capital Management Inc slightly increased its stake in Apple Inc. (NASDAQ:AAPL) during 2Q to 63,166 shares from 63,124 shares at the end of 1Q. The new position was valued at more than $7.9 million at the end of the latest quarter, compared to $7.85 million at the end of the previous quarter.

Stake in Sigma-Aldrich (SIAL) declines

Carderock Capital Management Inc cut its stake in Sigma-Aldrich Corporation (NASDAQ:SIAL), reporting 48,771 shares in the company at the end of 2Q. The fund owned 50,025 shares in Sigma-Aldrich at the end of 1Q, a stake valued at $6.92 million. The new stake in Sigma-Aldrich is valued at $6.80.

Stockholding in Novo Nordisk (NVO) increases

The stake in Novo Nordisk A/S (ADR) (NYSE:NVO) increased to 123,334 shares at the end of 2Q from 123,190 shares at the end of 1Q. The dollar value of the new stake stood at $6.75 million at the end of the latest quarter, compared to $6.58 million at the end of the previous quarter.

Neha Gupta

Neha Gupta has been in the financial space for over six years now. Gupta earned her MBA degree from Symbiosis Centre of Distance Learning in 2009 and her passion for finance led her to pursue Chartered Financial Analyst (CFA) course. She has successfully completed Level II of her CFA. She is a veteran in article writing, which is depicted in her numerous pieces published on SeekingAlpha, Nextiphonenews, InsiderMonkey, MarketWatch, and Techinsider. Her crisp and eloquent writing finds its best place in Researchcows, where emphasis is given on developing rich content for various websites, products, business plans, trainings, and book writing.

You may also like...

Toronto-Dominion Bank (TD), Royal Bank of Canada (RY) and Orange SA (ADR) (ORAN): Lincluden Management Ltd’s Top 3 Sells

Lincluden Management Ltd has reported in 2Q2015 regulatory filings that the value of its equity portfolio rose to $811.97 million...